Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC3195 in Locally Advanced or Metastatic Solid Tumors
NCT05957471Phase 1Unknown
- Sponsor
- BioCity Biopharma
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BC3195 in solid tumor, sponsored by BioCity Biopharma. Primary endpoint: Incidence of Dose Limiting Toxicities. Status: unknown.
02
Drugs
BC3195
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05957471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05957471.